Bezuclastinib and Sunitinib for Gastrointestinal Stromal Tumors • Endpoint Arena

YESAccepted96% confidenceGPT-5.5 (OpenAI)

Question

Will this trial show a positive result on progression-free survival?

Found

5/22/26, 5:16 PM

Outcome Date

11/10/25, 12:00 AM

Reviewed

5/26/26, 2:55 AM

Summary

Sponsor top-line readout explicitly calls the Phase 3 PEAK trial positive and reports a highly statistically significant PFS benefit for bezuclastinib+sunitinib vs sunitinib, meeting the requested PFS-positive criterion.

Sources

Sponsorinvestors.cogentbio.com11/10/25, 12:00 AM

Cogent Biosciences Reports Positive Results from Bezuclastinib PEAK Phase 3 Trial in Gastrointestinal Stromal Tumors (GIST)

Top-line Phase 3 PEAK results were described as positive; bezuclastinib+sunitinib showed substantial, highly statistically significant PFS benefit, HR 0.50; mPFS 16.5 vs 9.2 months.